CIBC Asset Management Inc Grows Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

CIBC Asset Management Inc boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,463 shares of the company’s stock after acquiring an additional 5,713 shares during the period. CIBC Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $1,900,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TEVA. New Covenant Trust Company N.A. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $28,000. EntryPoint Capital LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter worth about $30,000. UMB Bank n.a. boosted its stake in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $52,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

NYSE TEVA opened at $16.80 on Wednesday. The company has a 50-day moving average price of $17.75 and a 200-day moving average price of $17.28. Teva Pharmaceutical Industries Limited has a 52 week low of $9.04 and a 52 week high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The firm has a market capitalization of $19.03 billion, a P/E ratio of -19.76, a PEG ratio of 1.28 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays lifted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Finally, UBS Group upped their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.